|Articles|December 6, 2022
Further Discussion on Plasmids to Establish Release Specifications Using a Risk-Based Approach to Manage Supply
Author(s)Eurofins
A panel of experts from bio/pharmaceutical companies discuss plasmids to establish specifications using a risk-based approach to manage supply, including the response to cell & gene therapy industry feedback, future outlook and re-evaluating plasmid risks.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
